Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Glioma
Patients with glioma carrying mutations in either "IDH1" or "IDH2" have a relatively favorable survival, compared with patients with glioma with wild-type "IDH1/2" genes. In WHO grade III glioma, "IDH1/2"-mutated glioma have a median prognosis of ~3.5 years, whereas "IDH1/2" wild-type glioma perform poor with a median overall survival of c. 1.5 years. In glioblastoma, the difference is larger. There, "IDH1/2" wild-type glioblastoma have a median overall survival of 1 year, whereas "IDH1/2"-mutated glioblastoma have a median overall survival of more than 3 years.